SG/CALL/ELI LILLY & CO/380/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 20:39:35 20/06/2024 BST | ||
| 47.95 EUR | -1.82% |
|
| Current month | +15.77% | ||
| 1 month | +24.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 47.95 | -1.82% |
| 19/06/24 | 48.84 | +0.60% |
| 18/06/24 | 48.55 | +0.31% |
| 17/06/24 | 48.4 | +1.47% |
| 14/06/24 | 47.7 | -0.21% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 08:39 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ86XK |
| ISIN | DE000SQ86XK3 |
| Date issued | 16/02/2023 |
| Strike | 380 $ |
| Maturity | 17/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 5.38 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 49.45 € |
|---|---|
| Lowest since issue | 3.42 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
